Get the Stockscreener App
61.61
0.21%
0.13
Pre-market:
61.46
-0.15
-0.24%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $61.61, with a volume of 7.84M.
It is up +0.21% in the last 24 hours and down -1.99% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$61.48
Open:
$61.39
24h Volume:
7.84M
Relative Volume:
0.63
Market Cap:
$125.85B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
17.29
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-0.11%
1M Performance:
-1.99%
6M Performance:
+6.63%
1Y Performance:
+41.99%
1-Day Range:
$0.00
$0.00
1-Week Range:
$60.69
$63.59
52-Week Range:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
61.61 | 125.85B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,279.14 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.30 | 641.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
286.74 | 506.70B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
140.61 | 346.91B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.81 | 292.35B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Aug-05-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
3 Cheap Dividend Stocks I'd Buy Without Any Hesitation - The Motley Fool
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors - ChartMill
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study - BioSpace
Bristol Myers Iza-Bren Phase 3 PFS Reaches 11.1 Months - grafa.com
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Pathos AI Raises $237M at $3B Valuation in Round Led by Bristol Myers Squibb - citybiz
3 High-Yield Stocks to Buy With $1,000 Right Now - The Motley Fool
Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings? - The Motley Fool
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy - GlobeNewswire Inc.
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie - GlobeNewswire Inc.
Bristol Myers Squibb Co. CDR Overview (BMY) - Barron's
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Patient dies in Bristol Myers Squibb autoimmune CAR-T trial - STAT
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol Myers discloses patient death in early-stage cell therapy study - Reuters
What's Going On with Bristol Myers Squibb Stock on Friday? - Benzinga
Bristol Myers Reports CAR-T Death as Safety Concerns Mount - Bloomberg.com
Bristol-Myers Squibb Co: Following Data Cutof - Moomoo
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development - Reuters
Bristol Myers, SystImmune breast cancer drug cuts progression risk in study - Reuters
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Bristol-Myers Squibb Company (BMY) Options ChainYahoo Finance - Yahoo! Finance Canada
IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials - BioSpace
A Look at Bristol-Myers Squibb Co (BMY) After 3.1% Gain -- GF Va - GuruFocus
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue - The Motley Fool
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb shares may move 5.3% on earnings report By Investing.com - Investing.com Nigeria
Bristol-Myers Squibb shares may move 5.3% on earnings report - Investing.com
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility - The Motley Fool
Bristol Myers Squibb (BMY) Expected to Release Earnings on Thursday - MarketBeat
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio? - Zacks Investment Research
Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings (NYSE:BMY) - Seeking Alpha
Here's What I'm Planning With My Eli Lilly Position - The Motley Fool
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol-Myers Squibb Co (BMY) Shares Surge 4.8% -- What GF Score of 72 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Prothena's Partnership Strategy: Growth Driver or Limitation? - Zacks Investment Research
Bristol-Myers Squibb Co Stock (BMY) Moved Up by 3.39% on Oct 20: Key Drivers Unveiled - TradingKey
Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait. - The Motley Fool
Bristol Myers Squibb Company (NYSE:BMY) Stock Has Average Target Price of $64.88 According to Analysts - MarketBeat
Bristol Myers Squibb Company $BMY Stock: Assenagon Asset Management S.A. Raises Position - MarketBeat
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
RBC Capital reiterates Bristol-Myers Squibb stock rating at Sector Perform - Investing.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bristol Myers Squibb Co Stock (BMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Sep 09 '26 |
Sale |
64.57 |
6,249 |
403,498 |
18,748 |
| Massacesi Cristian | Officer |
Sep 09 '26 |
Proposed Sale |
64.57 |
6,249 |
403,498 |
0 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Sep 01 '26 |
Option Exercise |
66.92 |
1,236 |
82,713 |
13,317 |
| Holzer Phil M | Officer |
Aug 25 '26 |
Proposed Sale |
67.50 |
500 |
33,750 |
0 |
| Holzer Phil M | SVP and Controller |
Aug 25 '26 |
Sale |
67.50 |
500 |
33,750 |
16,862 |
| Gallman Cari | EVP, General Counsel |
Aug 01 '26 |
Option Exercise |
0.00 |
1,061 |
0 |
14,192 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Aug 01 '26 |
Option Exercise |
0.00 |
51,172 |
0 |
51,172 |
| Haller Julia A | Director |
Jun 15 '26 |
Option Exercise |
53.76 |
20,460 |
1,099,930 |
34,079 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Jun 03 '26 |
Option Exercise |
0.00 |
8,040 |
0 |
15,957 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
May 01 '26 |
Option Exercise |
0.00 |
1,373 |
0 |
20,508 |
0.69%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):